BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Entest Biomedical, Inc. Sees Entry into $300 Million Veterinary Cancer Care Market Through Veterinary Hospital Acquisitions


9/4/2012 9:34:35 AM

SAN DIEGO, CA--(Marketwire - September 04, 2012) - Entest BioMedical Inc. (PINKSHEETS: ENTB) (OTCQB: ENTB) a company focused on veterinary biotechnology and veterinary hospital acquisition / operation, announced today that it has begun the process of interviewing qualified candidates to fill the Company's newly created position of Director of Corporate Affairs.

A Company spokesman stated that, "The primary responsibilities of the Director of Corporate Affairs shall be to identify veterinary hospitals suitable for acquisition, substantially assist in the structuring of those acquisitions, and work with the company to integrate newly acquired veterinary hospitals into the Company. The Company's current business model involves acquiring veterinary clinics / hospitals to be utilized as potential distribution channels for its products under development. The Company believes that, in addition to serving as distribution channels for the Company's immuno-therapeutic cancer vaccine for canines, these clinics will be able to generate revenue for the Company from current operations."

"Our primary goal is to continue growing the number of Veterinary Hospitals we own," stated Dr. David Koos, Chairman and CEO of Entest BioMedical. "In pursuing this segment of our business model, we will be able to continue growing our asset base, increase our current revenue stream and establish an initial distribution channel for our products and therapies; the first of these products being Entest's ImenVax immune-therapeutic canine cancer vaccine currently under development. Having a qualified Director of Corporate Affairs whose duties will consist primarily of identifying hospitals for acquisition and who possesses the skills required to substantially assist us in negotiating favorable purchase terms will be valuable in assisting the Company in achieving its goal of acquiring up to 10 additional veterinary clinics within the next 16 months." Entest currently owns and operates the McDonald Animal Hospital of Santa Barbara, CA which the company purchased in 2011. This facility serves as both a revenue source for Entest as well as a research facility for the biomedical company.

Dr. Koos continued, "One in every three dogs will develop cancer during its lifetime. Sadly, such cancers kill nearly half of all pet dogs over the age of ten; animals that are family to millions of pet owners. Pet owners are willing to pay the cost for the necessary treatments meant to save the lives of their loved ones. We believe we will be able to provide families the needed cancer therapies for their canines, within the appropriate facilities, should we continue pursuing our growth model. With the ASPCA citing approximately 78 million dogs as pets within the United States, the veterinary care market represents enormous revenue potential. It has been estimated that the U.S. market for veterinary cancer care amounts to approximately $300 million per year."

Dr. Koos concluded, "Canine cancer impacts 60% of all dogs over six years of age in the United States (http://dogcanceradvice.com/canine-cancer-information/overview/). Cancer in canines is still predominantly treated through surgical excision, chemotherapy and radiation therapy. These treatment methods can be highly invasive and can result in numerous unpleasant side effects. We believe our products under development, which utilize the patient's own immune system to battle the cancer, will be able to offer a lower cost, less traumatic alternative to veterinarians and pet owners. As both the CEO of Entest and a loving pet owner my objectives are twofold; to contribute economic value to Entest as well as to contribute to the lifelong happiness of families who are pet owners."

About Entest BioMedical Inc.:

Entest BioMedical Inc. (PINKSHEETS: ENTB) (OTCQB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


Contact:

Entest BioMedical Inc.

David R. Koos
Chairman & CEO

619.702.1404 Direct
619.330.2328 Fax
Email Contact
www.EntestBio.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES